FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122330550> ?p ?o ?g. }

• W2122330550 endingPage "161" @default.
• W2122330550 startingPage "151" @default.
• W2122330550 abstract "Using the murine colon adenocarcinoma C-26 cell line, engineered to release granulocyte colony-stimulating factor (G-CSF) (C-26/G-CSF), were studied the mechanisms responsible for inhibition of tumor take in syngeneic animals and of regression of an established tumor in sublethally irradiated mice injected with these cells. Immunocytochemistry and in situ hybridization, performed to characterize tumor-infiltrating leukocytes and their cytokine expression, respectively, indicated that polymorphonuclear leukocytes (PMN) were the major cells responsible for inhibition of tumor take and that they expressed mRNA for interleukin 1 alpha (IL-1 alpha), IL-1 beta, and tumor necrosis factor alpha (TNF-alpha). Expression of interferon gamma (IFN-gamma) and of IL-4 was undetectable, consistent with the absence of T lymphocytes at the site of tumor injection. In mice injected with C-26/G-CSF cells after 600-rad irradiation, the tumors grew to approximately 1.5 cm in 30 d, regressing completely thereafter in 70-80% of mice. During the growing phase, tumors were infiltrated first by PMN (between days 15 and 20), then by macrophages, and last by T lymphocytes. Both CD4+ and CD8+ T cells were present but only CD8 depletion significantly abrogated tumor regression. Depletion of PMN by the RB6-8C5 antigranulocytes monoclonal antibody reduced the number of T cells infiltrating the tumor and prevented tumor regression. In situ hybridization performed at the beginning of tumor regression revealed the presence of mRNA for IL-1 alpha, IL-1 beta, and TNF-alpha, but also the presence of cells, with lymphoid morphology, expressing IFN-gamma. Tumors from mice treated with recombinant IFN-gamma (between days 20 and 35) were rejected faster, whereas mice treated with antibodies to IFN-gamma (from day 20) died of progressive tumor. Cyclosporin A treatment (started at day 20) also abrogated tumor regression. These results indicate that inhibition of tumor take and regression in this model occurs through different mechanisms that involve PMN and PMN-T cell interactions, respectively, as well as a combination of cytokines that, for tumor regression, require IFN-gamma. Thus, gene transfer of a single cytokine gene such as G-CSF into tumor cells appears to be sufficient to trigger the cascade of cell interactions and cytokine production necessary to destroy a cancer nodule." @default.
• W2122330550 created "2016-06-24" @default.
• W2122330550 creator A5024315497 @default.
• W2122330550 creator A5037837112 @default.
• W2122330550 creator A5038875205 @default.
• W2122330550 creator A5044524695 @default.
• W2122330550 creator A5057889361 @default.
• W2122330550 creator A5062210857 @default.
• W2122330550 creator A5071062410 @default.
• W2122330550 creator A5081264460 @default.
• W2122330550 date "1993-07-01" @default.
• W2122330550 modified "2023-10-14" @default.
• W2122330550 title "Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma." @default.
• W2122330550 cites W12754177 @default.
• W2122330550 cites W1493562779 @default.
• W2122330550 cites W1569506030 @default.
• W2122330550 cites W1573746155 @default.
• W2122330550 cites W1587762493 @default.
• W2122330550 cites W1590953592 @default.
• W2122330550 cites W1623244368 @default.
• W2122330550 cites W1625954412 @default.
• W2122330550 cites W1630308865 @default.
• W2122330550 cites W1895002748 @default.
• W2122330550 cites W1978563572 @default.
• W2122330550 cites W1986992784 @default.
• W2122330550 cites W1988637781 @default.
• W2122330550 cites W1989775015 @default.
• W2122330550 cites W2010290590 @default.
• W2122330550 cites W2011483230 @default.
• W2122330550 cites W2013266934 @default.
• W2122330550 cites W2016784633 @default.
• W2122330550 cites W2034319377 @default.
• W2122330550 cites W2042537047 @default.
• W2122330550 cites W2046555621 @default.
• W2122330550 cites W2054112116 @default.
• W2122330550 cites W2070570077 @default.
• W2122330550 cites W2084906660 @default.
• W2122330550 cites W2089457438 @default.
• W2122330550 cites W2095584949 @default.
• W2122330550 cites W2103385168 @default.
• W2122330550 cites W2105998729 @default.
• W2122330550 cites W2113537295 @default.
• W2122330550 cites W2128285805 @default.
• W2122330550 cites W2134445712 @default.
• W2122330550 cites W2140888976 @default.
• W2122330550 cites W2157154128 @default.
• W2122330550 cites W2168251609 @default.
• W2122330550 doi "https://doi.org/10.1084/jem.178.1.151" @default.
• W2122330550 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2191097" @default.
• W2122330550 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7686211" @default.
• W2122330550 hasPublicationYear "1993" @default.
• W2122330550 type Work @default.
• W2122330550 sameAs 2122330550 @default.
• W2122330550 citedByCount "166" @default.
• W2122330550 countsByYear W21223305502012 @default.
• W2122330550 countsByYear W21223305502013 @default.
• W2122330550 countsByYear W21223305502014 @default.
• W2122330550 countsByYear W21223305502015 @default.
• W2122330550 countsByYear W21223305502016 @default.
• W2122330550 countsByYear W21223305502017 @default.
• W2122330550 countsByYear W21223305502018 @default.
• W2122330550 countsByYear W21223305502019 @default.
• W2122330550 countsByYear W21223305502020 @default.
• W2122330550 countsByYear W21223305502021 @default.
• W2122330550 countsByYear W21223305502022 @default.
• W2122330550 countsByYear W21223305502023 @default.
• W2122330550 crossrefType "journal-article" @default.
• W2122330550 hasAuthorship W2122330550A5024315497 @default.
• W2122330550 hasAuthorship W2122330550A5037837112 @default.
• W2122330550 hasAuthorship W2122330550A5038875205 @default.
• W2122330550 hasAuthorship W2122330550A5044524695 @default.
• W2122330550 hasAuthorship W2122330550A5057889361 @default.
• W2122330550 hasAuthorship W2122330550A5062210857 @default.
• W2122330550 hasAuthorship W2122330550A5071062410 @default.
• W2122330550 hasAuthorship W2122330550A5081264460 @default.
• W2122330550 hasBestOaLocation W21223305501 @default.
• W2122330550 hasConcept C147483822 @default.
• W2122330550 hasConcept C153911025 @default.
• W2122330550 hasConcept C159654299 @default.
• W2122330550 hasConcept C167672396 @default.
• W2122330550 hasConcept C17991360 @default.
• W2122330550 hasConcept C203014093 @default.
• W2122330550 hasConcept C2777478134 @default.
• W2122330550 hasConcept C2777983669 @default.
• W2122330550 hasConcept C2778690821 @default.
• W2122330550 hasConcept C2780841837 @default.
• W2122330550 hasConcept C502942594 @default.
• W2122330550 hasConcept C542903549 @default.
• W2122330550 hasConcept C86803240 @default.
• W2122330550 hasConceptScore W2122330550C147483822 @default.
• W2122330550 hasConceptScore W2122330550C153911025 @default.
• W2122330550 hasConceptScore W2122330550C159654299 @default.
• W2122330550 hasConceptScore W2122330550C167672396 @default.
• W2122330550 hasConceptScore W2122330550C17991360 @default.
• W2122330550 hasConceptScore W2122330550C203014093 @default.
• W2122330550 hasConceptScore W2122330550C2777478134 @default.
• W2122330550 hasConceptScore W2122330550C2777983669 @default.
• W2122330550 hasConceptScore W2122330550C2778690821 @default.

• next